Experimental Hematology & Oncology
Scope & Guideline
Pioneering Insights in Hematology and Oncology
Introduction
Aims and Scopes
- Immunotherapy and Cellular Therapies:
The journal prominently features research on immunotherapeutic strategies, particularly CAR-T cell therapies and their applications in various blood cancers, reflecting a commitment to explore cutting-edge cellular therapies. - Molecular and Genetic Insights:
Emphasizing the role of genetic mutations and molecular pathways in cancer progression, the journal publishes studies that delve into the molecular underpinnings of hematological malignancies and their therapeutic implications. - Tumor Microenvironment and Metabolism:
Research on the tumor microenvironment, including interactions with immune cells and metabolic reprogramming, is a core focus area, highlighting the complexity of cancer biology and potential therapeutic targets. - Clinical Applications and Real-World Studies:
The journal prioritizes studies that translate laboratory findings into clinical practice, including multicenter trials and real-world outcomes of hematopoietic stem cell transplantation and novel therapeutic regimens. - Emerging Therapeutic Strategies:
It also explores novel therapeutic agents and combinations, including small molecules, bispecific antibodies, and targeted therapies, reflecting the journal's commitment to addressing evolving treatment landscapes.
Trending and Emerging
- Advancements in CAR-T Cell Therapy:
There is a significant trend towards exploring various aspects of CAR-T cell therapies, including novel constructs, combination therapies, and innovative delivery mechanisms, highlighting the potential for personalized cancer treatment. - Integrative Approaches to Tumor Microenvironment:
Increasing attention is being paid to the tumor microenvironment, with studies investigating how immune cells, stromal components, and metabolic factors influence tumor progression and therapy response. - Focus on Biomarkers and Precision Medicine:
Emerging themes include the identification of biomarkers for predicting treatment response and disease progression, emphasizing the shift towards precision medicine in hematological malignancies. - Role of Artificial Intelligence in Oncology:
Recent publications have begun to explore the application of AI and machine learning in diagnostics and treatment planning, indicating a growing interest in leveraging technology to enhance clinical outcomes. - Research on Novel Therapeutic Targets:
The journal is increasingly featuring studies on new therapeutic targets and pathways, particularly those involved in immune evasion and resistance mechanisms, reflecting a proactive approach to developing next-generation therapies.
Declining or Waning
- Traditional Chemotherapy Approaches:
Research focusing on standard chemotherapy regimens is becoming less frequent, as newer targeted therapies and immunotherapies gain traction and demonstrate improved efficacy and safety profiles. - Less Emphasis on Single-Agent Therapies:
There is a noticeable decline in studies centered on single-agent therapies, as combination therapies and multi-targeted approaches are increasingly recognized for their potential to overcome resistance. - Limited Exploration of Older Drug Classes:
The exploration of older drug classes and their mechanisms is waning, as the focus shifts towards innovative compounds and novel mechanisms of action that promise better clinical outcomes. - Decreased Interest in Basic Laboratory Models:
Research utilizing basic laboratory models without translational implications appears to be declining, as the journal emphasizes studies that bridge laboratory findings to clinical relevance. - Reduction in Studies on Rare Hematological Disorders:
There seems to be a decrease in the volume of research dedicated to rare hematological disorders, likely due to the concentration on more prevalent and impactful malignancies.
Similar Journals
INTERNATIONAL JOURNAL OF HEMATOLOGY
Pioneering Discoveries in Hematological ScienceThe INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.
EUROPEAN JOURNAL OF HAEMATOLOGY
Elevating Knowledge in Hematology Since 1986EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
Therapeutic Advances in Hematology
Transforming research into impactful therapies.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.
Molecular Therapy Oncolytics
Catalyzing Change in Cancer Treatment StrategiesMolecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.
Blood Cancer Discovery
Illuminating the Path to Understanding Blood MalignanciesBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
HEMATOLOGICAL ONCOLOGY
Connecting Researchers for a Cure in Hematological OncologyHEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.
Indian Journal of Hematology and Blood Transfusion
Elevating Knowledge: Your Source for Hematology ExcellenceIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Hematology-American Society of Hematology Education Program
Empowering Knowledge in Blood DisordersHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Hematologie
Unveiling New Insights in Hematological ResearchHematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.
AMERICAN JOURNAL OF HEMATOLOGY
Elevating Knowledge in Blood Health and TreatmentAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.